Vericiguat versus sacubitril/valsartan for the treatment of heart failure with reduced ejection fraction in China: a cost-utility analysis
On the standard treatment of heart failure, adding sacubitril/valsartan alone was more cost-effective than adding vericiguat alone for the treatment of HFrEF.
Authors
- Nan Hu (ORCID: https://orcid.org/0000-0002-7505-5001)
- Liying Wang (ORCID: https://orcid.org/0000-0002-4434-6498)
- Zongling Xia (ORCID: https://orcid.org/0009-0000-8356-5442)
- Xingyuan Zhao (ORCID: https://orcid.org/0000-0001-9679-2417)
Institutions
- Soochow University (TW)
- Soochow University (CN)
- The First People's Hospital of Changzhou (CN)
Publication Details
- Journal
- Acta cardiologica. Supplementum
- Published
- 2025-03-16
- DOI
- https://doi.org/10.1080/00015385.2025.2484848
- Citations
- 2
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.78